



## **HAS Healthcare Advanced Synthesis SA completes the acquisition of Cerbios-Pharma SA to establish a top-tier global group in the CDMO industry, backed by 65 Equity Partners**

- *This strategic transaction will pave the way for the establishment of a leading global group in the Contract Development and Manufacturing Organization (CDMO) industry.*
- *65 Equity Partners supports the merger, partnering with these family businesses and entrepreneurs in this acquisition and merger process to drive long-term company growth and innovation.*

**Biasca, Switzerland, May 7, 2025** – HAS Healthcare Advanced Synthesis SA ("HAS"), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, is pleased to announce today the successful completion of its previously announced acquisition of Cerbios-Pharma SA (Cerbios), a globally recognised manufacturer of chemical and biological APIs, including in the rapidly expanding area of antibody drug conjugates (ADCs).

This strategic transaction marks a significant milestone for the two companies and sets the stage for the creation of a leading global solutions provider in the Contract Development and Manufacturing Organization (CDMO) industry.

The acquisition is backed by 65 Equity Partners, a global investment firm dedicated to supporting family-owned businesses, founders, and entrepreneurs. Through this transaction, 65 Equity Partners becomes a c.40% shareholder alongside the Braglia family who retain majority control.

The alliance of the two Swiss-based companies, both with a global market presence, will drive innovation, accelerate extensive high-quality production capabilities, and deliver the cutting-edge chemical and biological expertise, technical excellence, and a wider range of services to address the dynamic needs of the global pharmaceutical industry.

The new group, driven by a dedicated workforce of over 400 people, embodies a strong corporate culture and family ownership values that have long defined both companies, with a firm commitment to Switzerland's Ticino region remaining at its core.

The two companies have now united their forces, maintaining the highest standards of quality and service, ensuring seamless integration and continued support for all customers with the same enthusiasm and commitment to excellence, enabling them to achieve new and significant milestones.

HAS was advised by Rothschild & Co (financial), Bär & Karrer (legal), and EY (accounting / tax).

65 Equity Partners was advised by UBS AG (financial), Ropes & Gray and Walder Wyss (legal), EY (accounting / tax), Pharmacloud and Guidance Pharm (commercial), JensonR+ (regulatory) and Orbsen (technical).

- Ends -

### **About HAS Healthcare Advanced Synthesis SA**

HAS Healthcare Advanced Synthesis, is a CDMO with four decades of international experience; the company offers a full range of customized services, from development to production. HAS Healthcare Advanced Synthesis SA develops and manufactures active pharmaceutical ingredients (APIs), highly potent active pharmaceutical ingredients (HPAPIs) and anticancer compounds.

The production site, founded in 1984, is located in Biasca, Switzerland. The facility is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. HAS operates dedicated production plants with production capacities ranging from a few hundred grams to tens of kilograms for highly potent active ingredients (HPAPIs) and anticancer compounds, and from kilograms to tens of tons for standard active ingredients (APIs); the plants are fully dedicated to cGMP production.

For more information visit our website <https://www.hashealthcare.com/> and follow us on [LinkedIn](#)

### **About Cerbios-Pharma SA**

Cerbios-Pharma SA (Cerbios) has almost 50 years of experience in the industry and expertise in developing and manufacturing generic APIs as well as offering CDMO services, manufacturing APIs, HPAPI, ADCs, and biological probiotics for the international human and animal market.

Cerbios has two production sites in Switzerland (Lugano, Headquarter and Couvet). Both facilities are regularly inspected by SwissMedic, the FDA and other global regulatory agencies. Cerbios has a specialized presence in the market as CDMO service provider, with dedicated production plants.

For more information visit our website <https://www.cerbios.ch/> and follow us on [LinkedIn](#)

### **About 65 Equity Partners**

65 Equity Partners is a global investment firm that partners with founders, families, and entrepreneurs across Europe, North America, and Asia to build sustainable, long-term value. We invest in leading businesses across the healthcare, industrial, business services, technology, and consumer sectors.

Backed by Temasek as an independently managed investment platform with US\$3.3 billion in funds under management, we provide equity and structured capital solutions to established companies with regional or global growth ambitions. With offices in London, Singapore, New York, and San Francisco, we leverage our local roots, international network and the deep expertise of our broader ecosystem.

For more information, visit our website at <https://www.65equitypartners.com/> and follow us on [LinkedIn](#).

*For further information, contact:*

### **HAS Healthcare Advanced Synthesis SA**

Biasca, Switzerland

#### **Press Office:**

Giacomo Braglia

Tel: +41 (0) 91 873 94 00

Email: [mediarelations@hashealthcare.com](mailto:mediarelations@hashealthcare.com)

### **65 Equity Partners**

Greenbrook

Peter Hewer, Theo Bryan, Long Tran

Email: [65EP@greenbrookadvisory.com](mailto:65EP@greenbrookadvisory.com)